BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27900634)

  • 1. SOCS2 polymorphisms are not associated with clinical and biochemical phenotypes in acromegalic patients.
    Trarbach EB; Jorge AA; Duarte FH; Bronstein MD; Jallad RS
    Pituitary; 2017 Jun; 20(3):319-324. PubMed ID: 27900634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the expression of suppressor of cytokine signalling (SOCS) 2 in the colonic mucosa of acromegalic patients are associated with hyperplastic polyps.
    Bogazzi F; Ultimieri F; Raggi F; Russo D; Costa A; Marciano E; Bartalena L; Martino E
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):898-906. PubMed ID: 18844680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and Turner syndrome: the influence of a SOCS2 polymorphism.
    Braz AF; Costalonga EF; Trarbach EB; Scalco RC; Malaquias AC; Guerra-Junior G; Antonini SR; Mendonca BB; Arnhold IJ; Jorge AA
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1808-13. PubMed ID: 24905066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressor of cytokine signaling-2 deficiency induces molecular and metabolic changes that partially overlap with growth hormone-dependent effects.
    Rico-Bautista E; Greenhalgh CJ; Tollet-Egnell P; Hilton DJ; Alexander WS; Norstedt G; Flores-Morales A
    Mol Endocrinol; 2005 Mar; 19(3):781-93. PubMed ID: 15563548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene polymorphisms of SOCS1 and SOCS2 and acute lymphoblastic leukemia.
    Chen SS; Wu WZ; Zhang YP; Huang WJ
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5564-5572. PubMed ID: 32495891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatments.
    Ramos-Leví AM; Marazuela M; Paniagua A; Quinteiro C; Riveiro J; Álvarez-Escolá C; Lúcas T; Blanco C; de Miguel P; Martínez de Icaya P; Pavón I; Bernabeu I
    Eur J Endocrinol; 2015 Feb; 172(2):115-22. PubMed ID: 25385818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplotype insufficiency for suppressor of cytokine signaling-2 enhances intestinal growth and promotes polyp formation in growth hormone-transgenic mice.
    Michaylira CZ; Ramocki NM; Simmons JG; Tanner CK; McNaughton KK; Woosley JT; Greenhalgh CJ; Lund PK
    Endocrinology; 2006 Apr; 147(4):1632-41. PubMed ID: 16410303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
    Montefusco L; Filopanti M; Ronchi CL; Olgiati L; La-Porta C; Losa M; Epaminonda P; Coletti F; Beck-Peccoz P; Spada A; Lania AG; Arosio M
    Clin Endocrinol (Oxf); 2010 May; 72(5):661-7. PubMed ID: 20447065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased linear bone growth by GH in the absence of SOCS2 is independent of IGF-1.
    Dobie R; Ahmed SF; Staines KA; Pass C; Jasim S; MacRae VE; Farquharson C
    J Cell Physiol; 2015 Nov; 230(11):2796-806. PubMed ID: 25833299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo.
    Michaylira CZ; Simmons JG; Ramocki NM; Scull BP; McNaughton KK; Fuller CR; Lund PK
    Am J Physiol Gastrointest Liver Physiol; 2006 Sep; 291(3):G472-81. PubMed ID: 16574995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer.
    Iglesias-Gato D; Chuan YC; Wikström P; Augsten S; Jiang N; Niu Y; Seipel A; Danneman D; Vermeij M; Fernandez-Perez L; Jenster G; Egevad L; Norstedt G; Flores-Morales A
    Carcinogenesis; 2014 Jan; 35(1):24-33. PubMed ID: 24031028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.
    Cinar N; Dagdelen S; Yorgun H; Canpolat U; Kabakçı G; Erbas T
    Pituitary; 2015 Feb; 18(1):116-25. PubMed ID: 24706164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly.
    Jallad RS; Trarbach EB; Duarte FH; Jorge AA; Bronstein MD
    Pituitary; 2015 Oct; 18(5):666-73. PubMed ID: 25552351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of IGF1-(CA)19 promoter microsatellite in the clinical presentation of acromegaly.
    Sala E; Filopanti M; Ferrante E; Barbieri AM; Malchiodi E; Verrua E; Giavoli C; Lania AG; Arosio M; Beck-Peccoz P; Spada A; Mantovani G
    Eur J Clin Invest; 2014 Dec; 44(12):1222-9. PubMed ID: 25370837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressor of cytokine signaling 2 (
    Dobie R; MacRae VE; Pass C; Milne EM; Ahmed SF; Farquharson C
    Dis Model Mech; 2018 Jan; 11(1):. PubMed ID: 29343614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17β-Estradiol positively modulates growth hormone signaling through the reduction of SOCS2 negative feedback in human osteoblasts.
    Bolamperti S; Mrak E; Moro G; Sirtori P; Fraschini G; Guidobono F; Rubinacci A; Villa I
    Bone; 2013 Jul; 55(1):84-92. PubMed ID: 23567159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct stimulation of bone mass by increased GH signalling in the osteoblasts of Socs2-/- mice.
    Dobie R; MacRae VE; Huesa C; van't Hof R; Ahmed SF; Farquharson C
    J Endocrinol; 2014 Oct; 223(1):93-106. PubMed ID: 25074853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.